68
https://pubmed.ncbi.nlm.nih.gov/38093413
A patient with metastatic Merkel cell carcinoma, refractory to single-agent PD-1/PD-L1 blockade, experienced a partial response to combined immunotherapy with ipilimumab plus nivolumab, as reported in this case study.
